Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128815 | 1.00 | CHRM1 (0.37) | CHRM1BCHECHRNB2CHRNA4CHRNA7 | |
| SCHEMBL29102843 | 0.77 | ATM (0.31) | — | |
| SCHEMBL19212123 | 0.77 | CHRM1 (0.40) | CHRM1BCHECHRNB2CHRNA4CHRNA7 | |
| SCHEMBL4779449 | 0.75 | CHRM1 (0.41) | CHRM1BCHECHRNB2CHRNA4CHRNA7 | |
| SCHEMBL28417988 | 0.75 | CHRM1 (0.41) | CHRM1BCHECHRNB2CHRNA4CHRNA7 | |
| SCHEMBL30688536 | 0.70 | — | — | |
| SCHEMBL4194315 | 0.70 | — | — | |
| SCHEMBL28572900 | 0.68 | CHRM1 (0.41) | CHRM1BCHECHRNB2CHRNA4CHRNA7 | |
| SCHEMBL23364994 | 0.67 | CHRNB2 (0.38) | CHRM1BCHECHRNB2CHRNA4CHRNA7 | |
| SCHEMBL9495273 | 0.67 | CHRM1 (0.55) | CHRM1BCHECHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436005-B2 | Macrocyclic pyrimidine derivatives | ABBOTT LABORATORIES (US) | 2013-05-07 | — | — | US | disclosed |
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253678-A1 | MACROCYCLIC PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | CHRM1 4847/4885BCHE 2677/4885CHRNB2 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.